New Modalities Nordic Investor Forum in September attracts top investors, academia and industry leaders – ”Interest is high – and rightly so"

..............................................................

GU Ventures sprider nyheter och information kring verksamheten, sina bolag, samt alumnibolag:

..............................................................

In September, the Nordic Life Science sector turns its attention to Gothenburg, where an inspiring event is generating great interest among investors, academia, and industry alike.

On September 2, the New Modalities Nordic Investor Forum will be held at GoCo Health Innovation City – an exclusive event carefully curated for investors eager to help drive the next era of medical development.

New Modality Support (NMS) – coordinated by GU Ventures in collaboration with CCRM Nordic, OligoNova, the Sahlgrenska Academy at the University of Gothenburg, and Sahlgrenska University Hospital – is organizing the forum together with the national platform SciLifeLab Drug Discovery & Development (DDD).

The timing couldn’t be better

Across the Nordics, there is a vibrant climate of innovation where new discoveries, technology, and investments intersect and interact. The forum focuses on the future of advanced therapeutics – New therapeutic modalities that are no longer on the fringes of science but are already reshaping the pharmaceutical industry's development strategies and opening up unique opportunities for the therapies of tomorrow.

“We are currently witnessing an unprecedented level of energy and innovation within the Nordic Life Science ecosystem. At the same time, international investors are turning their attention to the region, drawn by its therapeutic potential and the strength of our translational research infrastructure.” — Eduarde Rohner, PhD, NMS Lead, Business Development, GU Ventures

Interest is high – and rightly so

The response to the forum has been tremendous, with interest from both investors and strategic stakeholders. The event is designed to foster both dialogue and concrete collaborations, offering a unique opportunity to bring together visions from research, capital, and commercial application.

“The timing for this forum is not just good – it´s strategic. It is an opportunity to connect science, capital, and collaboration at a stage where the field of new therapy models is ready to take off.” — Carl-Peter Mattsson, Strategic Coordinator NMS, Investment Director, GU Ventures

A curated forum for visionaries

The day brings together leading industry players, pioneering academics, and investors to jointly address shared challenges in the future of drug development. Mårten Steen, MD, PhD, Managing Partner at HealthCap, and Lorenz Mayr, PhD, Managing Director at Mayr BioMedTech Consulting, are keynote speakers. Additionally, representatives from AstraZeneca, CCRM Nordic, Hadean Ventures, Industrifonden, Innovestor Life Science, Johnson & Johnson, Life Science Invest, Oslo Cancer Cluster, Ribocure Pharmaceuticals, the Sahlgrenska Academy, Skåne University Hospital, and Vinnova will also participate.

The next wave of innovation takes the stage

This isn’t just about presentations and panel discussions. A carefully selected group of Nordic startups in the pre-seed, seed, and Series A stages will be featured in a format that enables individual meetings with investors. What these companies have in common is that they are ready for partnerships and investments that could pave the way for the next major clinical breakthrough.

"The DDD platform contributes to high-quality, early-stage drug development where academic freedom is preserved while intellectual property rights are protected. Projects emerging from the DDD platform have a jumpstart in their commercial journey towards the clinics and for investors this means minimizing risks.” — Kristian Sandberg, PhD, Co-Director SciLifeLab DDD

About SciLifeLab DDD

The SciLifeLab Drug Discovery and Development (DDD) platform offers integrated drug discovery efforts to the Swedish academic research community. SciLifeLab DDD offer industry-standard infrastructure, expertise, and strategic support for technology development or to help progress projects towards a preclinical proof-of-concept within small molecules, human antibodies, and new modality therapeutics.

For more information, please visit: https://www.scilifelab.se/units/ddd-platform/

About New Modality Support (NMS)

NMS supports the further development and commercialization of individual research projects, primarily within the therapeutic oligonucleotide and ATMP sectors. By combining the experience and resources of participating parties with new, sector-specific expertise, value-creating services can be developed and deployed more efficiently. NMS is coordinated by GU Ventures and its partners are CCRM Nordic, OligoNova, Sahlgrenska Academy at the University of Gothenburg, and the Sahlgrenska University Hospital.

NMS is located at GoCo Health Innovation City in Mölndal and is supported by both the Västra Götaland Region through the Environment and Regional Development Board, as well as by the University of Gothenburg and GU Ventures. This support enables GU Ventures, the coordinator for NMS, to work strategically and sustainably towards the project ́s success.

For more information, please visit: https://newmodalitysupport.se